Intelligent Bio Solutions Resolves All Cybersecurity, Software-Related Review Items For Its Upcoming FDA Submission
Benzinga Newsdesk 3 months ago
FDANews
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has addressed
Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it has addressed all the cybersecurity and software-related review items for its upcoming FDA 510(k) submission. This follows the Company’s recent completion of independent third-party penetration testing and confirms that all review items have now been resolved. The Company is on track to submit its 510(k) notification in calendar H2 2026.